---
schema_version: "secwatch.filing_event.v1"
accession: "0000879169-25-000053"
form_type: "8-K"
ticker: "INCY"
cik: "0000879169"
company_name: "INCYTE CORP"
filed_at: "2025-04-29T23:59:59+00:00"
generated_at: "2026-05-23T04:30:35.626200+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Incyte Q1 2025 revenues up 20% to $1.05B; Jakafi guidance raised

## Summary
- Total revenues $1,053M (+20% YoY); product rev $922M (+26%); GAAP diluted EPS $0.80; Non-GAAP $1.16.
- Jakafi net product rev $709M (+24%); full-year 2025 guidance raised to $2,950-$3,000M.
- Opzelura net rev $119M (+38%); Niktimvo launch rev $14M in first two months.
- Povorcitinib meets primary endpoints in Phase 3 HS and Phase 2 CSU; supports regulatory submission.
- Cash and marketable securities $2.4B; pipeline progress across MPN, oncology, and IAI programs.

## SEC filing metadata
- accession: 0000879169-25-000053
- form_type: 8-K
- ticker: INCY
- cik: 0000879169
- company_name: INCYTE CORP
- filed_at: 2025-04-29T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/879169/000087916925000053/0000879169-25-000053-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/879169/000087916925000053/incy-20250429.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000879169-25-000053
- JSON: https://secwatch.observer/filing/0000879169-25-000053.json
- Plain text: https://secwatch.observer/filing/0000879169-25-000053.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.